Approval · Notice of Compliance 23562 · 2020
MINT-DUTASTERIDE: Notice of Compliance 23562
Issued May 7, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23562
- Date
- May 7, 2020
- Company
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Labelling Only
- Reason
- Update to inner and outer labels. update to product monograph
- Canadian reference product
- AVODART (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MINT-DUTASTERIDE | Not yet assigned | — |
Medicinal ingredients
- DUTASTERIDE 0.5 MG per CAP